Research Article
Mechanistic Investigation of Curcuma Protection against Oral Submucous Fibrosis

Haiyan Peng,1,2 Xiaowen Jiang,1,2 Linna Cui,1,2 Yali Zhu,1,2 Zhikui Ye,1,2 and Zhiming Zhang1,2

1Department of Stomatology, The First People’s Hospital of Chenzhou, the First Affiliated Clinical Medical College, Xiangnan University, Chenzhou, China
2Department of Oral and Maxillofacial Surgery, The Stomatology College, Southern Medical University, Guangzhou, China

Correspondence should be addressed to Xiaowen Jiang; jxw927@163.com

Received 11 July 2022; Revised 18 July 2022; Accepted 22 July 2022; Published 9 August 2022

Academic Editor: Weiguo Li

Copyright © 2022 Haiyan Peng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Oral submucous fibrosis (OSMF) is a chronic, fibrotic disease that affects the oral cavity, showing a high rate of malignant transformation. Curcuma exerts therapeutic potentials in many diseases including OSMF. However, the potential targets and pathways to explain the therapeutic effects of curcuma on OSMF are outside the scope of present knowledge. Herein we intend to reveal the predictive targets and potential pathways of curcuma against OSMF by a network pharmacology-based approach followed by molecular docking technology. Methods. We searched the SymMap, GeneCards, and OMIM database to obtain curcuma and OSMF common targets. The protein-protein interaction (PPI) of curcuma and OSMF common targets were then analyzed, followed by functional enrichment analysis. The best binding mode of curcuma and target proteins was analyzed by molecular docking technology. Results. We collected 290 putative targets of curcuma molecules and 600 known therapeutic targets of OSMF, with 64 curcuma and OSMF common targets sorted out. In the PPI network, there were 63 nodes with 922 edges. The node indicates protein and the line indicates PPI relation. The most enriched GO term in the BP level is “gland development”, followed by “cellular response to chemical stress”, and then “response to oxygen levels”, while the most enriched GO term in CC and MF is “membrane raft” and “cytokine receptor binding”, respectively. We also found 131 KEGG pathways significantly enriched by curcuma and OSMF common targets. The binding energy of curcuma to ALB, TNF, TP53, IL6, and VEGFA was −9.5 kcal/mol, −3.9 kcal/mol, −3.5 kcal/mol, −3.6 kcal/mol, and −8.9 kcal/mol, respectively, which suggested ALB and VEGFA were regarded as main targets involving in the potential mechanism of curcuma against OSMF. Conclusion. The present study illustrated that the therapeutic effects of curcuma on OSMF were achieved by targeting ALB and VEGFA, which giving reference to further drug design and development for OSMF.

1. Introduction

Oral submucous fibrosis (OSMF) is defined as a chronic scarring disease that severely affects the oral cavity, oropharynx, and sometimes the oesophagus [1, 2]. It represents a precancerous disorder and the transformation into oral squamous cell carcinoma has been found in 6%–30% cases of OSMF [1, 3]. OSMF is characterized by abnormal accumulation of collagen concomitant with progressive fibrosis in the submucosal connective tissues and limit mouth opening and tongue movement, leading to impingement on speech and swallowing [4]. OSMF is described as a multifactorial disease and mainly results from the habit of chewing betel quid and other areca nut containing products especially in Asian countries, lack of vitamin and iron, overconsumption of spicy food, and genetic susceptibility [5]. In China, men present a higher predisposition to OSF than women [6, 7]. The World Health Organization statistics, more than 5 million individuals are afflicted by OSMF worldwide, with age ranging from 8 to 80 years [8]. The mainstay of OSMF management is to minimize the annoying symptoms and increase the mouth opening to
improve the quality of life of patients and further prevent malignant transformation. The current treatment strategies for OSMF mainly includes drug treatment, mouth exercise physiotherapy, and elective surgery [9]. The primary clinical drugs to treat OSMF are corticosteroids, mainly focusing on ameliorating the inflammation and reducing the collagen formation in the oral tissue [10]. Several adjuvant agents including vitamins and vasodilators, aid to relieve the symptoms [11]. Mouth exercise physiotherapy alone or plus other modalities has been found to significantly increase the mouth opening [12]. Laser therapy has been introduced as a promising non-invasive technique to treat OSMF in modernized dentistry [13]. Recently, herbal derivatives or extracts have been studied by oral physicians to treat OSMF rather than commonly practiced intralesional steroids due to better patient compliance and better performance [14].

Curcumin, as a main bioactive polyphenolic compound, is extracted from the curcuma longa (also known as tumeric) that is a plant belonging to the ginger family (Zingiberaceae), originated from India, and currently grown in Southeast Asia and China [15]. Curcuma has attracted broad attention from ancient times as it owns profound biochemical and biological activities, such as antiviral, antimicrobial, anti-inflammatory, and antioxidant activities [16, 17]. Several investigations have revealed therapeutic implications of curcuma in several human diseases including diabetes [18], cancers [19], wound healing [19], rheumatic diseases [20], and ulcers [21]. Curcuma was previously studied in animal oral ulcer model, showing enhanced mucosal healing potentials [22]. Researchers treated rat models of OSMF with curcumol-loaded collage scaffold [23]. However, the potential targets and pathways to explain the therapeutic effects of curcuma on OSMF are outside the scope of present studies. Network pharmacology is burgeoning as an effective method to provide a systemic analysis of the pharmacokinetic properties of traditional Chinese medicine (TCM) by uncovering the interrelationship among drugs, targets, pathways, and disease [24]. Molecular docking is a drug design technology that simulates the geometric structure of molecules and estimates the best binding mode of small molecule drugs and its potential targets. Using both techniques in this study, we attempt to (i) construct OSMF interaction network with the targets of curcumol, (ii) decipher the mechanism elucidating the preventive role of curcuma against OSMF, and (iii) verify the potential targets of curcuma in treating OSMF.

2. Methods

2.1. Common Targets Mining. The SymMap database, accessed at http://www.symmap.org/, was retrieved to collect putative targets of curcuma. The proteins (only “Homo sapiens”) corresponding to the above active components were transformed into gene symbols using the UniProt database (https://www.UniProt.org/). The targets of OSMF were acquired from two public databases the GeneCards database (https://www.genecards.org/) and Online Mendelian Inheritance in Man database (OMIM, https://omim.org/). Briefly, we used “oral submucous fibrosis” as the search term to obtain disease targets (only “Homo sapiens”) in these two databases, with duplicates removed. The Venn diagram of the OSMF-associated targets and the putative targets of curcuma molecules was made using the R software to obtain curcuma and OSMF common targets and the corresponding network was visualized using Cytoscape software.

2.2. Protein-Protein Interaction (PPI) Network Construction. The curcuma and OSMF common targets were mapped into the STRING database, accessed at https://www.string-db.org/, to perform the PPI analysis. The PPI network was visualized by importing the tsv-based file to Cytoscape software (3.8.1). The species must be “Homo sapiens” and high confidence for interaction score must not less than 0.4. In the PPI network, nodes reflect proteins and connecting lines represent PPIs. The core genes ranked according to degree value obtained using cytoHubba plug-in of Cytoscape.

2.3. Functional Classification and Pathway Enrichment. Gene ontology (GO) functional analysis and pathway analysis based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) were implemented to harvest the potential functions of the disease-drug common targets by using the “clusterProfiler” package in the R software. The results of GO analysis were presented at the three levels: biological processes, molecular functions, and cellular components. The GO terms at three levels and significant KEGG pathways enrichments were ranked by P value, and the top 20 pathways and top 10 GO functions were visualized as bar plots and bubble plots using the “Pathview” package in R software.

2.4. Molecular Docking Technology. Molecular docking technology is a well-recognized method to examine receptor-ligand interactions along with binding patterns and affinities. Therefore, we performed molecular docking analysis between curcuma and the top core target genes in the PPI network. The pdb format of the 3D structure of the proteins encoded by the top core target genes were downloaded from the RCSB Protein Data Bank (PDB) database, accessed at https://www.rcsb.org/. Then, we converted the pdb-based files containing curcuma and the proteins encoded by core targets into pdbqt-based files and search for active pockets. The AutoDockTools was employed to determine the binding ability of ligands and receptors. The binding energy less than 0 indicates spontaneous binding of ligand and receptor, and smaller values reflect higher binding activity.

3. Results

3.1. Identification of Curcuma and OSMF Common Targets. After searching the SymMap database, we collected 290 putative targets of curcuma molecules in total and then convert these molecule names into gene symbols in the
UniProt database. With regard to the known therapeutic targets of OSMF, 600 targets were identified, with 578 collected in the GeneCards and 22 collected in the OMIM. Then, by using Venny 2.1 drawing software, we sorted 64 druggable targets of curcuma which were also therapeutic targets of OSMF (Figure 1(a)). We then used Cytoscape software to present disease-target-compound network (Figure 1(b)).

3.2. Key Targets in the PPI Network. We imported 64 curcuma and OSMF common targets into the STRING database for PPI analysis. As shown by the PPI network in Figure 2, there were 63 nodes with 922 edges, and those with higher degree values were regarded as core target genes.

3.3. Enrichment Analysis for Curcuma and OSMF Common Targets. Next, we further analyzed 64 curcuma and OSMF common targets by GO annotation and KEGG pathway analyses. After GO analysis, 1736 GO terms, in total, were found to be significantly enriched by curcuma and OSMF common targets ($P < 0.05$). Figure 3(a) lists the top 10 most enriched GO terms in the levels of BP, CC, and MF. The most enriched GO term in the BP level is “gland development”, followed by “cellular response to chemical stress”, and “cytokine receptor binding”, respectively. After KEGG pathway analysis, we found 131 KEGG pathways were enriched GO term in CC and MF is “membrane raft” and “response to oxygen levels”, while the most enriched GO term in the BP level is “gland development”. According to the principle of binding energy, a more negative docking score indicates a higher binding force between the compound and the protein. The affinity energy $≤ −5 \text{kcal/mol}$ is considered as high affinity, and thus ALB and VEGFA were regarded as main targets involving in the potential mechanism of curcuma against OSMF. The docking results are presented in a three-dimensional manner in Figure 4.

4. Discussion

Curcumin is the main component of turmeric (also known as curcuma longa), which is considered to be a non-toxic and safe substance for food uses and therapeutic purposes. Previous studies has proved its efficacy on various diseases such as type 2 diabetes mellitus [25], nonalcoholic fatty liver disease [26], and head and neck squamous cell carcinoma [27]. Although evidence indicated that Curcumin inhibited migration and metastasis of oral cancer cells [28], and turmeric oil and turmeric oleoresin exhibited antitumor activity in OSMF [29], few investigations have been done on the potential targets and pathways to clarify therapeutic value of curcuma against OSMF. Network pharmacology is a new and effective method, which changes the dogma of “one disease-one target-one drug”, and designs and analyses multi-target drug molecules to elaborate the mechanism of drug actions [30] in diseases such as diabetic nephropathy [31] and T-cell acute lymphoblastic leukemia [32]. As a silico structure-based approach, molecular docking strategies have been broadly applied to drug discovery process and identified new compounds with therapeutic significance [33].

In our study, according to network pharmacology method, we identified 64 common targets both acting on curcuma and OSMF through Venny 2.1 drawing software, and sorted the top 5 targets including ALB, TNF, TP53, IL6, and VEGFA as a result of PPI network. Human ALB gene encodes 609 amino acids and its expression is regulated by its promoter, transcription factor and intron. A case report of familial dysalbuminemic hyperthyroxinemia revealed that the patient showed extremely high serum free thyroxine concentration due to p.R242P mutation in the ALB gene [34]. Barasa et al. demonstrated that reduced serum ALB levels was found in HIV-1-infected patients following antiretroviral treatment, and this results might be attributed to rs1445776009 variants in the human ALB gene [35]. Furthermore, the role of ALB in cancers has been explored, for instance, the endometrial cancer patients with poor overall survival presented low serum ALB concentration, and ALB concentration was the independent prognostic factor for patients [36]. As reported by Bao et al. this prospective study concluded that ALB levels were negatively related to overall survival of oral cancer patients, exposing prognostic significance of ALB in oral cancer [37]. Similarly to previous study, elevated CRP/ALB ratio was observed in oral squamous cell carcinoma patients with poor overall survival [38]. TNF cytokine is a central regulator of immunity, which can promote inflammation. In the presence of pathogens, and inflammation and stress signals, TNF gene transcription is activated in a variety of cell types such as T cells, macrophages, and fibroblasts [39]. TNF-alpha located in the class III region of human leukocyte antigen belongs to TNF/TNFR cytokine family, and is involved in the malignant progression of disease. Like TNF cytokine, IL 6 type cytokine is essential for homeostasis and immunity maintenance. It is produced rapidly and instantaneously during infection and tissue injury, which promotes host defense by stimulating acute phase reaction, hematoapoiesis and immune response [40]. TNF-alpha acts as a pathogenic role in the development of OSMF, a condition of precancerous lesions [41]. Increased risk of oral precancerous lesions, such as leukoplakia, oral lichen planus, and OSMF, was induced by TNF-α (−308) and IL-6 gene polymorphism [42]. Compared with healthy controls, the patients with oral lichen planus, oral leukoplakia, or OSMF all had elevated serum and salivary levels of TNF-α and IL-6 [43], and the findings were supported by another research, revealing that
TNF-α and IL-6 levels increased in OSMF patients [44]. TP53 is a tumor suppressor gene and TP53 gene mutations, especially somatic mutation of TP53 gene, are responsible for more than 50% of human tumors [45]. TP53 mutation is considered as a potential prognostic and predictive marker along with a target of drug intervention in cancers. Varun et al. pointed out that mean labeling index of P53 for OSMF patients with OSMF showed significantly higher mean se-

logistic levels of VEGFA than that in healthy controls. In the present study, we performed molecular docking method to evaluate the binding energy of curcuma to the top
5 targets, and ALB with $-9.5 \text{kcal/mol}$ and VEGFA with $-8.9 \text{kcal/mol}$ stood out. Previous studies manifested that the conjugation of curcuma and ALB increased the aqueous solubility of the drug, leading to favorable immunomodulatory activity with increase in total leukocyte count, platelet count, and viable cell count in bone marrow. Besides, this
conjugation was helpful to inhibit tumor deterioration in model of mice with Dalton’s lymphoma ascites [49]. Oral administration of curcumol-based supplement is a safe and effective anti-VEGF treatment in age-related macular degeneration, resulting in functional outcome improvement [50]. The results in our study revealed that ALB and VEGFA might be the main targets participating in the potential mechanism of curcuma against OSMF.

Of note, our study has several limitations. First, the findings in our study obtained by a network pharmacology-based approach followed by molecular docking technology need to be verified in cellular and animal model. Second, we need more database screening common targets to improve the reliability of analysis or gene expression profiling of OSMF sample compared to control can be used to obtain more validated targets of OSMF. Third, the expression patterns of ALB, TNF, TP53, IL6, and VEGFA, the regulation of curcuma on these targets in the setting of OSMF are warranted to receive experimental validation. Forth, the exact therapeutic mechanism of curcuma against OSMF should be clearly explained in the future, such as anti-inflammatory, antioxidant, or wound healing effects. Network pharmacology has been widely used for drug-target-pathway analysis [51], where we again emphasize the importance of this field for medical research.

5. Conclusion

In conclusion, the study illustrated that the therapeutic effects of curcuma on OSMF were achieved by targeting ALB and VEGFA. Accordingly, the study thoroughly elucidated the molecular mechanism responsible for the therapeutic effects of curcuma on OSMF, which not only can facilitate the design and application of curcuma but also may bring more profound therapeutics for minimize the symptoms and healing oral mucosal lesion thus improving mouth opening in the context of OSMF.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

This study was supported by the Natural Science Foundation of Hunan Province (2022J0090, 2022J0091), the Oral cancer and precancerous lesions diagnosis and treatment technology research center of Chenzhou, the Science and Technology Bureau Research Project of Chenzhou Municipal (ZDYF2020057), the Research Project of the First People’s Hospital of Chenzhou (CZYY202204, CZYY202209), and the Clinical Research Project of the First People’s Hospital of Chenzhou (2021B011, 2021B014, 2022KJ-019, 2022KJ-242).

References

[1] V. Murthy, P. Mylonas, B. Carey et al., “Malignant transformation rate of oral submucous fibrosis: a systematic review and meta-analysis,” Journal of Clinical Medicine, vol. 11, pp. 1793–1797, 2022.
[2] Q. Peng, H. Li, J. Chen, Y. Wang, and Z. Tang, “Oral submucous fibrosis in Asian countries,” Journal of Oral Pathology & Medicine, vol. 49, no. 4, pp. 294–304, 2020.
[3] L. K. Bijai and A. Muthukrishnan, “Potential role of fibroblast senescence in malignant transformation of oral submucous fibrosis,” Oral Oncology, vol. 127, Article ID 105810, 2022.
[4] L. Saso, A. Reza, E. Ng et al., “A comprehensive analysis of the role of oxidative stress in the pathogenesis and chemoprevention of oral submucous fibrosis,” Antioxidants, vol. 11, p. 868, 2022.
[5] J. G. Ray, R. Chatterjee, and K. Chaudhuri, “Oral submucous fibrosis: a global challenge. Rising incidence, risk factors, management, and research priorities,” Periodontology 2000, vol. 80, no. 1, pp. 200–212, 2019.
[6] X. Cai, Z. Yao, G. Liu, L. Cui, H. Li, and J. Huang, “Oral submucous fibrosis: a clinicopathological study of 674 cases in China,” Journal of Oral Pathology & Medicine, vol. 48, no. 4, pp. 321–325, 2019.
[7] B. Liu, M. Shen, J. Xiong et al., “Synergistic effects of betel quid chewing, tobacco use (in the form of cigarette smoking), and alcohol consumption on the risk of malignant transformation of oral submucous fibrosis (OSF): a case-control study in Hunan province, China,” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol. 120, no. 3, pp. 337–345, 2015.
[8] N. K. Nigam, K. Aravinda, M. Dhillon, S. Gupta, S. Reddy, and M. Srinivas Raju, “Prevalence of oral submucous fibrosis among habitual gutka and areca nut chewers in Moradabad district,” Journal of Oral Biology and Craniofacial Research, vol. 4, no. 1, pp. 8–13, 2014.
[9] Y. W. Shen, Y. H. Shih, L. J. Fuh, and T. M. Shieh, “Oral submucous fibrosis: a review on biomarkers, pathogenic mechanisms, and treatments,” International Journal of Molecular Sciences, vol. 21, no. 7231, p. 19, 2020.
[10] W. M. Tilakaratne, R. P. Ekanayaka, M. Herath, R. D. Jayasinghe, M. Sithiquee, and H. Amarasinghe, “Intralesional corticosteroids as a treatment for restricted mouth opening in oral submucous fibrosis,” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol. 122, no. 2, pp. 224–231, 2016.
[11] R. H. Chole, S. M. Gondivkar, A. R. Gadbail et al., “Review of drug treatment of oral submucous fibrosis,” Oral Oncology, vol. 48, no. 5, pp. 393–398, 2012.
[12] P. G. Patil, V. Hazarey, R. Chaudhari, and S. Nimbalkar-Patil, “A randomized control trial measuring the effectiveness of a mouth-exercising device for mucosal burning in oral submucous fibrosis,” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol. 122, no. 6, pp. 713–718, 2016.
[13] S. Gupta and M. K. Jawanda, “Laser as a promising non-invasive technique to treat oral submucous fibrosis: a systematic review of the literature,” The Saudi Dental Journal, vol. 33, no. 7, pp. 413–423, 2021.
[14] R. Rajesh Kashyap and R. Shanker Kashyap, “Herbal derivatives in the management of mouth opening in oral submucous fibrosis—a network meta-analysis,” Oral Diseases, vol. 27, no. 7, pp. 1606–1615, 2021.
[15] S. M. Solomon, C. S. Stafie, I. G. Sufaru et al., “Curcumin as a natural approach of periodontal adjunctive treatment and its
immunological implications: a narrative review,” *Pharmaceuticals*, vol. 14, no. 5, p. 982, 2022.

[16] A. Zia, T. Farkhondeh, A. M. Pourbagher-Shahri, and S. Samarghandian, “The role of curcumin in aging and senescence: molecular mechanisms,” *Biomedicine & Pharmacotherapy*, vol. 134, Article ID 111119, 2021.

[17] R. R. Kotha and D. L. Luthria, “Curcumin: biological, pharmaceutical, nutraceutical, and analytical aspects,” *Molecules*, vol. 24, no. 2930, p. 16, 2019.

[18] R. N. Thota, S. H. Acharya, and M. L. Garg, “Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial,” *Lipids in Health and Disease*, vol. 18, no. 1, p. 31, 2019.

[19] R. Aromokeye and H. Si, “Combined curcumin and luteolin synergistically inhibit colon cancer associated with Notch1 and TGF-beta signaling pathways in cultured cells and xenograft mice,” *Cancers*, vol. 14, no. 3001, p. 12, 2022.

[20] S. Tomaras, G. Keker, and E. Feist, “Curcumin: useful add-on for rheumatic diseases?” *Journal of Clinical Medicine*, vol. 11, no. 2908, p. 10, 2022.

[21] M. Mukhtar, R. Razaghi, and M. Momen-Heravi, “The effects of curcumin intake on wound healing and metabolic status in patients with diabetic foot ulcer: a randomized, double-blind, placebo-controlled trial,” *Phytotherapy Research*, vol. 35, no. 4, pp. 2099–2107, 2021.

[22] Y. S. Lim, S. K. Kwon, J. H. Park, C. G. Cho, S. W. Park, and W. K. Kim, “Enhanced mucosal healing with curcumin in animal oral ulcer model,” *The Laryngoscope*, vol. 126, no. 2, pp. E68–E73, 2016.

[23] M. Mardani, A. Sadeghzadeh, N. Tanideh, et al., “The effects of adipose tissue-derived stem cells seeded onto the curcumin-loaded collagen scaffold in healing of experimentally-induced oral mucosal ulcers in rat,” *Iran J Basic Med Sci*, vol. 23, no. 12, pp. 1618–1627, 2020.

[24] A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” *Nature Chemical Biology*, vol. 4, no. 11, pp. 682–690, 2008.

[25] F. Pivari, A. Mingione, C. Brasacchio, and L. Soldati, “Curcumin and type 2 diabetes mellitus: prevention and treatment,” *Nutrients*, vol. 11, no. 1837, p. 8, 2019.

[26] S. Rahmani, S. Asgary, G. Askari et al., “Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial,” *Phytotherapy Research*, vol. 30, no. 9, pp. 1540–1548, 2016.

[27] R. Wilken, M. S. Veena, M. B. Wang, and E. S. Srivatsan, “Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma,” *Molecular Cancer*, vol. 10, no. 1, p. 12, 2011.

[28] A. Davoodvandi, M. Farshadi, N. Zare et al., “Antimetastatic effects of curcumin in oral and gastrointestinal cancers,” *Frontiers in Pharmacology*, vol. 12, Article ID 668567, 2021.

[29] K. Hastak, N. Lubri, S. D. Jakhkhi et al., “Effect of turmeric oil and turmeric oleoresin on cytogenetic damage in patients suffering from oral submucous fibrosis,” *Cancer Letters*, vol. 116, no. 2, pp. 265–269, 1997.

[30] C. Nogales, Z. M. Mamdouh, M. List, C. Kiel, A. I. Casas, and H. H. Schmidt, “Network pharmacology: curing causal mechanisms instead of treating symptoms,” *Trends in Pharmacological Sciences*, vol. 43, no. 2, pp. 136–150, 2022.

[31] L. Zhang, L. Han, X. Wang et al., “Exploring the mechanisms underlying the therapeutic effect of Salvia miltiorrhiza in diabetic nephropathy using network pharmacology and molecular docking,” *Bioscience Reports*, vol. 41, no. BSR20203520, p. 6, 2021.

[32] Y. Gocho, J. Liu, J. Hu et al., “Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia,” *Naturelle Canadien*, vol. 2, no. 3, pp. 284–299, 2021.

[33] L. Pinzi and G. Rastelli, “Molecular docking: shifting paradigms in drug discovery,” *International Journal of Molecular Sciences*, vol. 20, no. 4331, p. 18, 2019.

[34] S. Abali, Z. Yavas Abali, K. Yararbas, and S. Semiz, “Rapid molecular diagnosis of ALB gene variants prevents unnecessary interventions in familial dysalbuminemic hyperthyroxinemia,” *Journal of Pediatric Endocrinology & Metabolism*, vol. 34, no. 9, pp. 1201–1205, 2021.

[35] E. Barasa, N. Shaviya, V. Budambula, and T. Were, “rs1445776009 variants in the human ALB gene: association with serum albumin and clinical outcomes in HIV-infected Kenyan injection substance users,” *International Journal of Health Sciences*, vol. 15, no. 3, pp. 3–11, 2021 May-Jun.

[36] J. Lei, Y. Wang, X. Guo et al., “Low preoperative serum ALB level is independently associated with poor overall survival in endometrial cancer patients,” *Future Oncology*, vol. 16, no. 8, pp. 307–316, 2020.

[37] X. Bao, F. Liu, J. Lin et al., “Nutritional assessment and prognosis of oral cancer patients: a large-scale prospective study,” *BMC Cancer*, vol. 20, no. 1. p. 146, 2020.

[38] Q. Wang, X. Song, Y. Zhao et al., “Preoperative high c-reactive protein/albumin ratio is a poor prognostic factor of oral squamous cell carcinoma,” *Future Oncology*, vol. 15, no. 19, pp. 2277–2286, 2019.

[39] J. V. Falvo, A. V. Tsytysyova, and A. E. Goldfeld, “Transcriptional control of the TNF gene,” *Current Directions in Autoimmunity*, vol. 11, pp. 27–60, 2010.

[40] P. C. Heinrich, I. Behrmann, S. Haan, H. M. Hermanns, G. Muller-Newen, and F. Schaper, “Principles of interleukin (IL)-6-type cytokine signalling and its regulation,” *Biochemical Journal*, vol. 374, no. 1, pp. 1–20, 2003.

[41] C. J. Chiu, C. P. Chiang, M. L. Chang et al., “Association between genetic polymorphism of tumor necrosis factor-a and risk of oral submucous fibrosis, a pre-cancerous condition of oral cancer,” *Journal of Dental Research*, vol. 80, no. 12, pp. 2055–2059, 2001.

[42] H. J. Hsu, Y. H. Yang, T. Y. Shieh et al., “Role of cytokine gene (interferon-γ, transforming growth factor-β1, tumor necrosis factor-a, interleukin-6, and interleukin-10) polymorphisms in the risk of oral precancerous lesions in Taiwanese,” *The Kaohsiung Journal of Medical Sciences*, vol. 30, no. 11, pp. 551–558, 2014.

[43] J. Kaur and R. Jacobs, “Proinflammatory cytokine levels in oral lichen planus, oral leukoplakia, and oral submucous fibrosis,” *J Korean Assoc Oral Maxillofac Surg*, vol. 41, no. 4, pp. 171–175, 2015.

[44] M. F. Haque, S. Meghji, U. Khitab, and M. Harris, “Oral submucous fibrosis patients have altered levels of cytokine production,” *Journal of Oral Pathology & Medicine*, vol. 29, no. 3, pp. 123–128, 2000.

[45] B. Leroy, M. Anderson, and T. Soussi, “TP53 mutations in human cancer: database reassessment and prospects for the next decade,” *Human Mutation*, vol. 35, no. 6, pp. 672–688, 2014.

[46] B. R. Varun, K. Ranganathan, U. K. Rao, and E. Joshua, “Immunohistochemical detection of p53 and p63 in oral squamous cell carcinoma, oral leukoplakia, and oral
submucous fibrosis,” *Journal of Investigative and Clinical Dentistry*, vol. 5, no. 3, pp. 214–219, 2014.

[47] A. Almangush, I. Heikkinen, A. A. Makitie et al., “Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis,” *British Journal of Cancer*, vol. 117, no. 6, pp. 856–866, 2017.

[48] S. R. Gupta, A. Sharma, N. Gupta, and K. Mani, “Single nucleotide polymorphisms and serologic levels of hypoxia-inducible factor1 alpha and vascular endothelial growth factor are associated with increased risk of oral submucous fibrosis in gutka users among a North Indian population,” *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, vol. 130, no. 5, pp. 557–564, 2020.

[49] S. R. Aravind and L. K. Krishnan, “Curcumin-albumin conjugates as an effective anti-cancer agent with immunomodulatory properties,” *International Immunopharmacology*, vol. 34, pp. 78–85, 2016.

[50] D. Allegrini, R. Raimondi, M. Angi et al., “Curcuma-based nutritional supplement in patients with neovascular age-related macular degeneration,” *Journal of Medicinal Food*, vol. 24, no. 11, pp. 1191–1196, 2021.

[51] P. Bing, W. Zhou, and S. Tan, “Study on the mechanism of Astragalus polysaccharide in treating pulmonary fibrosis based on “Drug-Target-Pathway” network,” *Frontiers in Pharmacology*, vol. 13, Article ID 865065, 2022.